The most recent filing that the Great West Life Assurance Company has made with the SEC reveals that during the third quarter, the company increased its holdings in Bruker Co. (NASDAQ: BRKR) by 8.6%. Following the completion of the transaction, the business entity owned a total of 68,278 shares of stock in the medical research company.
During that time frame, the corporation made an additional purchase of 5,390 shares of stock. The value of the holdings in Bruker that Great West Life Assurance Co. owned as of the end of the most recent reporting period was determined to be $3,620,000. This value was determined after the end of the most recent reporting period.
Recent transactions involving other significant investors involved the buying and selling business stock. These transactions took place recently.
During the third quarter of 2018, Wipfli Financial Advisors LLC invested $25,000 in Bruker.
Bruker was the recipient of this investment. Zions Bancorporation National Association invested approximately $26,000 in Bruker during the first three months of 2018 to acquire a new stake in the company.
During the second quarter, Ronald Blue Trust Inc.
Invested approximately 31,000 dollars in the purchase of additional shares of Bruker. Householder Group Estate & Retirement Specialist LLC increased its holdings in Bruker during the third quarter by purchasing additional shares for roughly $32,000. This was done to diversify the company’s holdings.
Last but not least, CoreCap Advisors LLC put approximately $52,000 toward purchasing additional stock in Bruker during the second quarter. To the tune of 70.40 percent, the company shares are owned by institutional investors and hedge funds.
When trading started on Tuesday, the price of a share of Bruker stock was $73.03. The company’s market capitalization is currently sitting at $10.74 billion; it has a price-to-earnings ratio of 39.91, a price-to-earnings-to-growth ratio of 2.39, and a beta value of 1.18. The moving average of the stock price over the past fifty days is $67.20, and the moving average over the past two hundred days is $62.40. The debt-to-equity ratio, the current ratio, and the quick ratio all come in at 1.20, but the quick ratio comes in at 1.49. The quick ratio is the most important of these three ratios.
During the previous year, the price of Bruker Co. fell to its lowest point of $48.52 while it reached its highest point of $74.94.
Bruker (NASDAQ: BRKR) released its most recent earnings report for its most recent fiscal quarter on Thursday, November 3. The medical research company reported earnings per share for the quarter to be $0.66, which was $0.13 more than the analysts’ consensus estimate. The company reported a revenue of $638.90 million for the quarter, which is significantly higher than the consensus estimate of $613.53 million provided by industry analysts. The numbers for Bruker came out as follows: a return on equity of 32.58% and a net margin of 10.97%.
According to the projections of specialized research analysts, each share of Bruker Co. stock will bring in a profit of $2.32 in 2017.
In addition, on December 16, the company announced the distribution of a quarterly dividend, which was paid out on the same day. On December 1, dividends of $0.05 were distributed to shareholders who had their shares recorded by the company. This results in a dividend payment of 0.20 cents per year and a yield of 0.27%. When expressed on an annual basis. The day before the dividend was paid out, the 30th of the month, the ex-dividend date for this dividend was the previous Wednesday. Currently, Bruker is paying out dividends to its shareholders, amounting to 10.93% of the company’s earnings.
Many analysts have conducted extensive research on BRKR stock, and the findings have been discussed here.
In a research note released on Wednesday, November 16, Cowen announced that they had lowered their price objective on Bruker stock to $75.00. The rating that TheStreet had previously assigned to Bruker’s stock, a “c+,” was raised to a “b-” in a research report published on November 4 by TheStreet. The research note covering Bruker shares was published by UBS Group on October 21, making it the first day it was publicly available. They recommended that the company “buy” the stock and establish a price objective of $70.00.
In a report on the company’s stock published online on November 7, StockNews.com upgraded its recommendation on the shares of Bruker from “buy” to “strong-buy,” indicating a higher level of interest in the stock. The company’s stock has received nine buy ratings from investment analysts, including five buy ratings, one strong buy rating, one sell rating, and four buy ratings.
According to the information made available by Bloomberg, the company is currently being given an average rating of “Moderate Buy,” with a target price of $74 established for itself.
Cynthia M. Friend, a director at Bruker, is reported to have sold 921 shares of the company’s stock on Tuesday, January 17, according to additional news regarding Bruker. The shares were sold for a total of $62,867.46, based on an average price of $68.26 per share, which was determined by dividing the total amount by the number of shares sold. Following the conclusion of the sale, the director is now the direct owner of 11,576 shares of the company. The total value of these shares is $790,177.76.
If you follow this link, you will be taken to the filing submitted to the Securities and Exchange Commission, where the transaction was discussed, and it will take you there immediately.
It was announced on Tuesday, December 6, that Director Richard A.
Packer had sold 20,000 shares of the company’s stock, which brings us to yet another piece of information concerning Bruker. The total amount obtained from the sale of the shares was $1,323,600.00, which comes out to $66.18 for each share.
As a direct result of the transaction, the director now owns 59,907 shares, with an estimated market value of $3,964,645.26.
If you follow this link, you will be taken to the filing submitted to the Securities and Exchange Commission, where the transaction was discussed, and it will take you there immediately. Cynthia M. Friend, who serves as a director of the company in addition to her other responsibilities, sold 921 shares of the company’s stock on Tuesday, January 17, 2018. The shares were sold on the open market for a total price of $68.26 each, which brings the total to $62,867.46. Following the completion of the transaction, the director will have a total of 11,576 shares in the company, which will be worth a combined sum of $790,177.76 at present.
Disclosures that are related to the sale might be found in this section of the website. The percentage of the total ownership in the company currently held by employees of the company is 26.60%.